SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 17 February 2026,
London UK
GSK plc announces the fourth tranche of share buyback
programme
On 24 February 2025, GSK plc ("GSK") announced the commencement of a £2 billion
share buyback programme (the "Programme"), as announced in its 2024 full year results
announcement published on 5 February 2025. The Programme is to be
implemented over the period to the end of Q2
2026.
The first tranche of the Programme (of up to £0.7 billion)
commenced on 24 February 2025; the second tranche of the Programme
(of up to £0.45 billion) commenced on 4 June 2025; and the
third tranche of the Programme (of up to £0.3 billion)
commenced on 30 September 2025. The first, second and third
tranches of the Programme completed in accordance with their
terms.
GSK announces that the fourth tranche of the Programme of up to
£0.45 billion will commence today.
GSK has entered into a non-discretionary agreement with BNP Paribas
S.A. ("BNPP"), enabling GSK to buy back ordinary shares of
31¼ pence each in GSK ("Ordinary
Shares") with an aggregate
value of up to £0.45 billion (the "Fourth
Tranche"). Purchases of
Ordinary Shares under the Fourth Tranche are expected to commence
on 17 February 2026 and to be completed by 24 April
2026.
The purpose of the Programme is to return excess capital to
shareholders and reduce the share capital of the company, and it is
expected that the implementation of the Programme will enhance
earnings per share. Ordinary Shares purchased under the Fourth
Tranche will be held as Treasury shares.
BNPP will make trading decisions in relation to the Fourth Tranche
independently of GSK with regard to the timing of
purchases. Any
purchase of Ordinary Shares by BNPP contemplated by this
announcement will be carried out on the London Stock Exchange
and/or Cboe Europe Limited through the BXE and CXE order books. Any
purchases of Ordinary Shares by GSK from BNPP under the Fourth
Tranche will be carried out on the London Stock
Exchange.
The Fourth Tranche will be effected within certain pre-set
parameters and in accordance with GSK's general authority to
repurchase shares and will be conducted within the parameters
prescribed by the Market Abuse Regulation 596/2014, the Commission
Delegated Regulation (EU) 2016/1052 (both as incorporated into UK
domestic law by the European Union (Withdrawal) Act 2018) as well
as applicable laws and the regulations of the UK Financial Conduct
Authority (including Chapter 9 of the Listing Rules).
The Fourth Tranche will occur within the limitations of GSK's
existing general authority to repurchase up to 413,957,879 Ordinary
Shares granted at its 2025 Annual General Meeting.
No repurchases will be made in the United States of America or in
respect of GSK's American Depositary Receipts.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 7780 494750
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q4 Results for 2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
17, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
